prostaglandin-d2 has been researched along with 5-oxo-6-8-11-14-eicosatetraenoic-acid* in 6 studies
6 other study(ies) available for prostaglandin-d2 and 5-oxo-6-8-11-14-eicosatetraenoic-acid
Article | Year |
---|---|
Biosynthesis and actions of 5-oxoeicosatetraenoic acid (5-oxo-ETE) on feline granulocytes.
The 5-lipoxygenase product 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is the most powerful human eosinophil chemoattractant among lipid mediators and could play a major pathophysiological role in eosinophilic diseases such as asthma. Its actions are mediated by the OXE receptor, orthologs of which are found in many species from humans to fish, but not rodents. The unavailability of rodent models to examine the pathophysiological roles of 5-oxo-ETE and the OXE receptor has substantially hampered progress in this area. As an alternative, we have explored the possibility that the cat could serve as an appropriate animal model to investigate the role of 5-oxo-ETE. We found that feline peripheral blood leukocytes synthesize 5-oxo-ETE and that physiologically relevant levels of 5-oxo-ETE are present in bronchoalveolar lavage fluid from cats with experimentally induced asthma. 5-Oxo-ETE (EC50, 0.7nM) is a much more potent activator of actin polymerization in feline eosinophils than various other eicosanoids, including leukotriene (LT) B4 and prostaglandin D2. 5-Oxo-ETE and LTB4 induce feline leukocyte migration to similar extents at low concentrations (1nM), but at higher concentrations the response to 5-oxo-ETE is much greater. Although high concentrations of selective human OXE receptor antagonists blocked 5-oxo-ETE-induced actin polymerization in feline granulocytes, their potencies were about 200 times lower than for human granulocytes. We conclude that feline leukocytes synthesize and respond to 5-oxo-ETE, which could potentially play an important role in feline asthma, a common condition in this species. The cat could serve as a useful animal model to investigate the pathophysiological role of 5-oxo-ETE. Topics: Actins; Allergens; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acids; Asthma; Benzeneacetamides; Benzothiazoles; Bronchoalveolar Lavage Fluid; Cats; Chemotaxis; Cynodon; Disease Models, Animal; Eosinophils; Female; Gene Expression; Humans; Leukotriene B4; Male; Neutrophils; Polymerization; Primary Cell Culture; Prostaglandin D2; Receptors, Eicosanoid | 2015 |
Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils.
D prostanoid receptor 2 (DP₂) [also known as chemoattractant receptor-homologous molecule expressed on T helper 2 (Th2) cells (CRTH2)] is selectively expressed by Th2 lymphocytes, eosinophils, and basophils and mediates recruitment and activation of these cell types in response to prostaglandin D₂ (PGD₂). (5-Fluoro-2-methyl-3-quinolin-2-ylmethylindo-1-yl)-acetic acid (OC000459) is an indole-acetic acid derivative that potently displaces [³H]PGD₂ from human recombinant DP₂ (K(i) = 0.013 μM), rat recombinant DP₂ (K(i) = 0.003 μM), and human native DP₂ (Th2 cell membranes; K(i) = 0.004 μM) but does not interfere with the ligand binding properties or functional activities of other prostanoid receptors (prostaglandin E₁₋₄ receptors, D prostanoid receptor 1, thromboxane receptor, prostacyclin receptor, and prostaglandin F receptor). OC000459 inhibited chemotaxis (IC₅₀ = 0.028 μM) of human Th2 lymphocytes and cytokine production (IC₅₀ = 0.019 μM) by human Th2 lymphocytes. OC000459 competitively antagonized eosinophil shape change responses induced by PGD₂ in both isolated human leukocytes (pK(B) = 7.9) and human whole blood (pK(B) = 7.5) but did not inhibit responses to eotaxin, 5-oxo-eicosatetraenoic acid, or complement component C5a. OC000459 also inhibited the activation of Th2 cells and eosinophils in response to supernatants from IgE/anti-IgE-activated human mast cells. OC000459 had no significant inhibitory activity on a battery of 69 receptors and 19 enzymes including cyclooxygenase 1 (COX1) and COX2. OC000459 was found to be orally bioavailable in rats and effective in inhibiting blood eosinophilia induced by 13,14-dihydro-15-keto-PGD₂ (DK-PGD₂) in this species (ED₅₀ = 0.04 mg/kg p.o.) and airway eosinophilia in response to an aerosol of DK-PGD₂ in guinea pigs (ED₅₀ = 0.01 mg/kg p.o.). These data indicate that OC000459 is a potent, selective, and orally active DP₂ antagonist that retains activity in human whole blood and inhibits mast cell-dependent activation of both human Th2 lymphocytes and eosinophils. Topics: Animals; Apoptosis; Arachidonic Acids; Binding, Competitive; Calcium Signaling; Cell Membrane; Cell Shape; Chemokine CCL11; Chemotaxis; CHO Cells; Complement C5a; Cricetinae; Culture Media, Conditioned; Eosinophilia; Eosinophils; Guinea Pigs; Humans; Indoleacetic Acids; Interleukin-13; Interleukin-5; Leukotriene B4; Lymphocyte Activation; Mast Cells; Prostaglandin Antagonists; Prostaglandin D2; Pulmonary Eosinophilia; Quinolines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Immunologic; Receptors, Prostaglandin; Recombinant Proteins; Th2 Cells; Transfection | 2012 |
Hierarchy of eosinophil chemoattractants: role of p38 mitogen-activated protein kinase.
Several chemoattractants can regulate the recruitment of eosinophils to sites of inflammation, but the hierarchy among them is unknown. We observed here that eosinophil chemotaxis towards eotaxin or 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) was amplified up to sixfold in the presence of prostaglandin (PG) D2. This effect was only seen in eosinophils, and not in neutrophils or basophils. Pretreatment with the chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) antagonist ramatroban prevented the PGD2 enhancement of eosinophil migrations. In contrast, eotaxin or 5-oxo-ETE inhibited the migration of eosinophils towards PGD2. 5-oxo-ETE enhanced the chemotaxis to eotaxin, while eotaxin had no effect on 5-oxo-ETE-induced migration. 5-oxo-ETE induced the phosphorylation of p38 mitogen-activated protein kinase, and inhibition of p38 mitogen-activated protein kinase by SB-202190 converted the effect of 5-oxo-ETE on the chemotaxis to PGD2 from inhibition to enhancement. The presence of blood or plasma markedly decreased the sensitivity of eosinophils to eotaxin or 5-oxo-ETE, while responses to PGD2 were unaltered. In conclusion, PGD2 might be an initial chemoattractant, since it maintains its potency in the circulation and augments the responsiveness of eosinophils to other chemoattractants. In contrast, eotaxin seems to be an end-point chemoattractant, since it has reduced efficacy in blood and is capable of down-modulating eosinophil responsiveness to other chemoattractants. Topics: Arachidonic Acids; Carbazoles; Chemokine CCL11; Chemokines, CC; Chemotactic Factors, Eosinophil; Chemotaxis, Leukocyte; Eosinophils; Humans; p38 Mitogen-Activated Protein Kinases; Platelet Aggregation Inhibitors; Prostaglandin D2; Sulfonamides | 2006 |
Effects of prostaglandin D(2) and 5-lipoxygenase products on the expression of CD203c and CD11b by basophils.
Basophils are important in allergic diseases such as asthma because they produce a variety of inflammatory mediators. Activation of these cells with IgE and N-formyl-methionyl-leucyl-phenylalanine results in a variety of responses, including increased surface expression of CD203c and CD11b and release of histamine. Although considerable information is available on the effects of eicosanoids on neutrophils, eosinophils, and monocytes, less is known about their effects on basophils. In the present study, we examined the effects of various eicosanoids on the above basophil responses. Of the naturally occurring eicosanoids tested, prostaglandin D(2) (PGD(2); EC(50), 10 nM) was by far the most potent activator of CD203c expression, with other prostanoids having little effect. This response was mediated by the DP(2) receptor/chemoattractant receptor-homologous molecule expressed on Th2 cells because it was shared by the selective agonist 15R-methyl-PGD(2) (EC(50), 3 nM). The 5-lipoxygenase products leuko-triene B(4) and 5-oxo-6,8,11,14-eicosatetraenoic acid also stimulated CD203c expression but to a lesser extent than PGD(2), whereas leukotriene D(4) was inactive. Neither PGD(2) nor 5-oxo-6,8,11,14-eicosatetraenoic acid stimulated histamine release or CD63 expression on basophils. Both PGE(2) and the DP(1) receptor agonist BW245C [(4S)-(3-[(3R,S)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid] strongly inhibited DP(2) receptor-mediated CD203c expression. The DP(1) receptor antagonist BWA868C [3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)-4-imidazolidine-heptanoic acid] enhanced PGD(2)-induced CD203c expression, suggesting that interaction of PGD(2) with DP(1) receptors can limit activation of basophils by this prostaglandin. In conclusion, PGD(2) is the most potent inducer of basophil CD203c expression among eicosanoids and may be a key mediator in asthma and other allergic diseases. The balance between DP(1) and DP(2) receptors may be important in determining the magnitude of basophil responses to this prostaglandin. Topics: Antigens, Surface; Arachidonate 5-Lipoxygenase; Arachidonic Acids; Basophils; Biotransformation; CD11b Antigen; Dinoprostone; Flow Cytometry; Histamine Release; Humans; Phosphoric Diester Hydrolases; Prostaglandin D2; Pyrophosphatases; Receptors, Prostaglandin | 2005 |
5-Oxo-ETE analogs and the proliferation of cancer cells.
MDA-MB-231, MCF7, and SKOV3 cancer cells, but not HEK-293 cells, expressed mRNA for the leukocyte G protein-coupled 5-oxo-eicosatetraenoate (ETE) OXE receptor. 5-Oxo-ETE, 5-oxo-15-OH-ETE, and 5-HETE stimulated the cancer cell lines but not HEK-293 cells to mount pertussis toxin-sensitive proliferation responses. Their potencies in eliciting this response were similar to their known potencies in activating leukocytes and OXE receptor-transfected cells. However, high concentrations of 5-oxo-ETE and 5-oxo-15-OH-ETE, but not 5-HETE, arrested growth and caused apoptosis in all four cell lines; these responses were pertussis toxin-resistant. The same high concentrations of the oxo-ETEs but again not 5-HETE also activated peroxisome proliferator-activated receptor (PPAR)-gamma. Pharmacological studies indicated that this activation did not mediate their effects on proliferation. These results are the first to implicate the OXE receptor in malignant cell growth and to show that 5-oxo-ETEs activate cell death programs as well as PPARgamma independently of this receptor. Topics: Anilides; Apoptosis; Arachidonic Acids; Binding Sites; Caspase 3; Caspases; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression; Humans; Hydroxyeicosatetraenoic Acids; Mitosis; Peroxisome Proliferator-Activated Receptors; Pertussis Toxin; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; PPAR gamma; Prostaglandin D2; Protein Binding; Receptors, Eicosanoid; Transfection | 2005 |
15-Deoxy-delta 12,14-prostaglandins D2 and J2 are potent activators of human eosinophils.
15-Deoxy-Delta(12,14)-PDJ(2) (15d-PGJ(2)) is a degradation product of PGD(2) that has been proposed as an anti-inflammatory compound because of its various inhibitory effects, some of which are mediated by peroxisome proliferator-activated receptor-gamma. In contrast to its reported inhibitory effects on macrophages and other cells, we found that this compound is a potent activator of eosinophils, inducing calcium mobilization, actin polymerization, and CD11b expression. It is selective for eosinophils, having little or no effect on neutrophils or monocytes. 15d-PGJ(2) has an EC(50) of approximately 10 nM, similar to that of its precursor, PGD(2). The concentrations of 15d-PGJ(2) required to activate eosinophils are thus much lower than those required for its anti-inflammatory effects (usually micromolar). 15-Deoxy-Delta(12,14)-prostaglandin D(2) (15d-PGD(2)) is also a potent activator of eosinophils, with an EC(50) about the same as that of PGD(2), whereas Delta(12)-PGJ(2) is slightly less potent. Eosinophils pretreated with PGD(2) no longer respond to 15d-PGJ(2), and vice versa, but in both cases the cells still respond to another eicosanoid proinflammatory mediator, 5-oxo-6,8,11,14-eicosatetraenoic acid. This indicates that the effects of 15d-PGJ(2) are mediated by the DP(2)/chemoattractant receptor-homologous molecule expressed on Th2 cells that has recently been identified in eosinophils. 15d-PGJ(2) is selective for the DP(2) receptor, in that it has no effect on DP(1) receptor-mediated adenylyl cyclase activity in platelets. We conclude that 15d-PGJ(2) and 15d-PGD(2) are selective DP(2) receptor agonists that activate human eosinophils with potencies at least 100 times greater than those for the proposed anti-inflammatory effects of 15d-PGJ(2) on other cells. Topics: Actins; Arachidonic Acids; Calcium; Calcium Signaling; Cyclic AMP; Eosinophils; Humans; Macrophage-1 Antigen; Polymers; Prostaglandin D2; Receptors, Immunologic; Receptors, Prostaglandin | 2002 |